BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32336824)

  • 1. Background parenchymal enhancement: behavior during neoadjuvant chemotherapy for breast cancer and relationship with a pathological complete response.
    Teixeira SRC; de Camargo Júnior HSA; Cabello C
    Radiol Bras; 2020; 53(2):95-104. PubMed ID: 32336824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Choi JS; Ko ES; Ko EY; Han BK; Nam SJ
    Medicine (Baltimore); 2016 Mar; 95(9):e3000. PubMed ID: 26945421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy.
    Rella R; Bufi E; Belli P; Scrofani AR; Petta F; Borghetti A; Marazzi F; Valentini V; Manfredi R
    Diagn Interv Imaging; 2022 Oct; 103(10):486-494. PubMed ID: 35585020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy.
    Rella R; Bufi E; Belli P; Petta F; Serra T; Masiello V; Scrofani AR; Barone R; Orlandi A; Valentini V; Manfredi R
    Diagn Interv Imaging; 2020 Oct; 101(10):649-655. PubMed ID: 32654985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.
    You C; Gu Y; Peng W; Li J; Shen X; Liu G; Peng W
    Acta Radiol; 2018 Jul; 59(7):806-812. PubMed ID: 29065702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy.
    Oh SJ; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
    Br J Radiol; 2018 Jul; 91(1088):20170550. PubMed ID: 29848015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Background Parenchymal Enhancement and Pathologic Complete Remission Throughout the Neoadjuvant Chemotherapy in Breast Cancer Patients.
    You C; Peng W; Zhi W; He M; Liu G; Xie L; Jiang L; Hu X; Shen X; Gu Y
    Transl Oncol; 2017 Oct; 10(5):786-792. PubMed ID: 28806712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.
    Chen JH; Yu H; Lin M; Mehta RS; Su MY
    Magn Reson Imaging; 2013 Nov; 31(9):1465-71. PubMed ID: 23992630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response.
    Preibsch H; Wanner L; Bahrs SD; Wietek BM; Siegmann-Luz KC; Oberlecher E; Hahn M; Staebler A; Nikolaou K; Wiesinger B
    Eur Radiol; 2016 Jun; 26(6):1590-6. PubMed ID: 26382845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
    Onishi N; Li W; Newitt DC; Harnish RJ; Strand F; Nguyen AA; Arasu VA; Gibbs J; Jones EF; Wilmes LJ; Kornak J; Joe BN; Price ER; Ojeda-Fournier H; Eghtedari M; Zamora KW; Woodard S; Umphrey HR; Nelson MT; Church AL; Bolan PJ; Kuritza T; Ward K; Morley K; Wolverton D; Fountain K; Lopez Paniagua D; Hardesty L; Brandt KR; McDonald ES; Rosen M; Kontos D; Abe H; Sheth D; Crane E; Dillis C; Sheth P; Hovanessian-Larsen L; Bang DH; Porter B; Oh KY; Jafarian N; Tudorica LA; Niell B; Drukteinis J; Newell MS; Giurescu ME; Berman E; Lehman CD; Partridge SC; Fitzpatrick KA; Borders MH; Yang WT; Dogan B; Goudreau SH; Chenevert T; Yau C; DeMichele A; Berry DA; Esserman LJ; Hylton NM
    Radiology; 2021 Nov; 301(2):295-308. PubMed ID: 34427465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ring Enhancement in Non-Neoplastic Breast Tissue on MRI During Neoadjuvant Chemotherapy for Breast Cancer: Incidence and Clinical Implications.
    Oh J; Han BK; Ko EY; Ko ES; Choi JS; Kim H; Park YH; Kim JY
    Acad Radiol; 2023 Dec; 30(12):2931-2939. PubMed ID: 37045651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Background Parenchymal Enhancement at Dynamic Contrast-enhanced MRI in Predicting Breast Cancer Recurrence Risk.
    Arefan D; Zuley ML; Berg WA; Yang L; Sumkin JH; Wu S
    Radiology; 2024 Jan; 310(1):e230269. PubMed ID: 38259203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative background parenchymal enhancement to predict recurrence after neoadjuvant chemotherapy for breast cancer.
    Moliere S; Oddou I; Noblet V; Veillon F; Mathelin C
    Sci Rep; 2019 Dec; 9(1):19185. PubMed ID: 31844135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
    Choi BB; Kim SH
    Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.
    Arasu VA; Kim P; Li W; Strand F; McHargue C; Harnish R; Newitt DC; Jones EF; Glymour MM; Kornak J; Esserman LJ; Hylton NM;
    J Breast Imaging; 2020 Aug; 2(4):352-360. PubMed ID: 32803155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of radiotherapy on background parenchymal enhancement in breast magnetic resonance imaging.
    Kim YJ; Kim SH; Choi BG; Kang BJ; Kim HS; Cha ES; Song BJ
    Asian Pac J Cancer Prev; 2014; 15(7):2939-43. PubMed ID: 24815428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Background Parenchymal Enhancement at Contrast-Enhanced Spectral Mammography (CESM) as a Breast Cancer Risk Factor.
    Sorin V; Yagil Y; Shalmon A; Gotlieb M; Faermann R; Halshtok-Neiman O; Sklair-Levy M
    Acad Radiol; 2020 Sep; 27(9):1234-1240. PubMed ID: 31812577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Associated With Background Parenchymal Enhancement on Contrast-Enhanced Mammography.
    Karimi Z; Phillips J; Slanetz P; Lotfi P; Dialani V; Karimova J; Mehta T
    AJR Am J Roentgenol; 2021 Feb; 216(2):340-348. PubMed ID: 32755162
    [No Abstract]   [Full Text] [Related]  

  • 19. Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer.
    Wu S; Berg WA; Zuley ML; Kurland BF; Jankowitz RC; Nishikawa R; Gur D; Sumkin JH
    Breast Cancer Res; 2016 Jul; 18(1):76. PubMed ID: 27449059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Background Parenchymal Enhancement of the Contralateral Normal Breast: Association with Tumor Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
    Chen JH; Yu HJ; Hsu C; Mehta RS; Carpenter PM; Su MY
    Transl Oncol; 2015 Jun; 8(3):204-9. PubMed ID: 26055178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.